Mostrar el registro sencillo del ítem

dc.contributor.authorSerafini, Michele Aramburupt_BR
dc.contributor.authorPaz, Ana Helena da Rosapt_BR
dc.contributor.authorNunes, Natália Schneiderpt_BR
dc.date.accessioned2022-04-13T04:51:46Zpt_BR
dc.date.issued2022pt_BR
dc.identifier.issn2666-3546pt_BR
dc.identifier.urihttp://hdl.handle.net/10183/237172pt_BR
dc.description.abstractInflammatory bowel diseases (IBD) are chronic intestinal disorders characterized by dysregulated immune responses to resident microbiota in genetically susceptible hosts. The activation of the cholinergic system has been proposed for the treatment of IBD patients according to its potential anti-inflammatory effect in vivo. The α-7-nicotinic-acetylcholine receptor (α7nAChR) is involved in the inhibition of inflammatory processes, modulating the production of cytokines, suppressing dendritic cells and macrophage activity, leading to the suppression of T cells. In this review, we address the most recent studies and clinical trials concerning cholinergic signaling and its therapeutic potential for inflammatory bowel diseases.en
dc.format.mimetypeapplication/pdfpt_BR
dc.language.isoengpt_BR
dc.relation.ispartofBrain, behavior, & immunity - health. [New York]. Vol. 19 (Feb. 2022), 100401, 10 p.pt_BR
dc.rightsOpen Accessen
dc.subjectCholinergic signalingen
dc.subjectDoenças inflamatórias intestinaispt_BR
dc.subjectImunomodulacaopt_BR
dc.subjectInflammatory bowel diseasesen
dc.subjectMacrophageen
dc.subjectColinérgicospt_BR
dc.subjectT cellen
dc.subjectEstimulação do nervo vagopt_BR
dc.subjectImmunomodulationen
dc.subjectAcetylcholineen
dc.subjectVagus nerveen
dc.subjectIntestinal immunityen
dc.subjectα-7-Nicotinic-acetylcholine receptoren
dc.titleCholinergic immunomodulation in inflammatory bowel diseasespt_BR
dc.typeArtigo de periódicopt_BR
dc.identifier.nrb001138101pt_BR
dc.type.originEstrangeiropt_BR


Ficheros en el ítem

Thumbnail
   

Este ítem está licenciado en la Creative Commons License

Mostrar el registro sencillo del ítem